Clinical Research Directory
Browse clinical research sites, groups, and studies.
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
Sponsor: Ruijin Hospital
Summary
To evaluate the efficacy of CMV-specific T cell immunity test in prolonged usage of letermovir for avoiding late-onset csCMVi after all-HSCT.
Official title: CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After Allogeneic Hematopoietic Stem Cell Transplantation
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2024-07-01
Completion Date
2026-06-01
Last Updated
2025-12-15
Healthy Volunteers
No
Conditions
Interventions
Letermovir
letermovir stops when CMI\>1.5
Locations (5)
Tongji Hospital of Huazhong University of Science and Technology, Wuhan
Wuhan, Hubei, China
Ruijin Hospital of Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
The First Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, China
Shanghai Liquan Hospital
Shanghai, China